AI assistant
Altimmune, Inc. — Director's Dealing 2024
Jan 5, 2024
33207_dirs_2024-01-04_03ea4b09-7b23-489a-9d9f-8414b4d94fd4.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Altimmune, Inc. (ALT)
CIK: 0001326190
Period of Report: 2024-01-01
Reporting Person: Jordt Raymond M (Chief Business Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-01-01 | Common Stock, par value $0.0001 | M | 9375 | — | Acquired | 11207 | Direct |
| 2024-01-01 | Common Stock, par value $0.0001 | F | 2503 | $11.25 | Disposed | 8704 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-01-01 | Restricted Stock Units | $ | M | 9375 | Disposed | Common Stock, par value $0.0001 (9375) | Direct |
Footnotes
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested.
F2: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs.
F3: The RSUs become vested and exercisable over four (4) years with 25% of the shares vesting on January 1, 2024, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.